This page is presented for educational purposes and is not meant to describe Novo Nordisk products.

 
 
 

treating adult growth hormone deficiency (AGHD)

 
 

Childhood Onset GHD

Adult Growth Hormone Deficiency (AGHD) is classified as either Childhood Onset (CO) or Adult Onset (AO).

Adult Growth Hormone Deficiency (AGHD) patients classified as Childhood Onset (CO) are those who were GH deficient during childhood as a result of congenitial, genetic, acquired, or idiopathic causes.
Treatment should be continued until adult height is achieved or until there is no longer a clinical response.

 

Adult Onset GHD

Adults may be initiated on growth hormone therapy to treat GHD not previously diagnosed during childhood, to treat CO GHD requiring further treatment as adults, or to treat newly acquired GHD (adult onset) after a health crisis. Adults may receive therapy to treat metabolic conditions, which may include increased visceral fat, diminished lean body mass (LBM), decreased bone mineral density (BMD), and adverse cardiovascular disease (CVD) risk factors.1

 

References

  1. Gharib H, Cook DM, Saenger PH, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children–2003 update. Endocrin Pract. 2003;9(1):64-76.